title: Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension.
abstract: BACKGROUND
  The angiotensin receptor antagonist fimasartan lowered blood pressure (BP) in a previous large population study. The purpose of this study was to evaluate whether fimasartan treatment for 3 months affects clinical and home BP variability in addition to reducing BP.
  
  
  METHODS
  The study enrolled 1,396 patients (mean age 56.2±10.0 years; males 53.6%) with mild-to-moderate hypertension who had a complete set of home BP measurements (morning and evening) and metabolic risk evaluation. During the 3 months of study, fimasartan alone was used to control BP at a daily dose of 30-120 mg. Clinical and home BP measurements were performed before and after the 3-month treatment. BP variability included beat-to-beat variability (clinical) and day-to-day variability (home).
  
  
  RESULTS
  Fimasartan reduced BP after 3 months of treatment. The average reduction of clinical systolic BP (c-SBP) was 15.08±18.36 mmHg (P<0.0001), and the average reduction of morning home SBP (m-SBP) was 11.49±19.33 mmHg (P<0.0001). Beat-to-beat variability as standard deviation (SD) of c-SBP was reduced from 4.56±3.22 to 4.24±3.11 mmHg (P=0.0026). Day-to-day variability as SD of m-SBP was reduced from 7.92±6.74 to 6.95±4.97 mmHg (P<0.0001). Multiple regression analysis revealed an independent association between the change in the SD of c-SBP and the change in c-SBP (P=0.0268) and, similarly, between the change in the SD of m-SBP and the change in m-SBP (P=0.0258), after adjusting for age, sex, body mass index, and change in mean BP.
  
  
  CONCLUSIONS
  This study indicated that 3 months of fimasartan treatment reduced day-to-day BP variability independent of BP reduction in patients with hypertension.
authors.affiliation: Division of Cardiology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea.
authors.forename: Mi-Seung
authors.initials: MS
authors.lastname: Shin
authors.affiliation: Office of Biostatistics, Ajou University School of Medicine, Suwon, South Korea.
authors.forename: Dae Ryong
authors.initials: DR
authors.lastname: Kang
authors.affiliation: Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, South Korea.
authors.forename: Changsoo
authors.initials: C
authors.lastname: Kim
authors.affiliation: Division of Cardiology, Department of Internal Medicine, St Paul's Hospital, Catholic University of Korea, Seoul, South Korea.
authors.forename: Eun Joo
authors.initials: EJ
authors.lastname: Cho
authors.affiliation: Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
authors.forename: Ki-Chul
authors.initials: KC
authors.lastname: Sung
authors.affiliation: Cardiology Division, Severance Cardiovascular Hospital and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
authors.forename: Seok-Min
authors.initials: SM
authors.lastname: Kang
authors.affiliation: Division of Cardiology, Paik Hospital, Inje University College of Medicine, Busan, South Korea.
authors.forename: Dong-Soo
authors.initials: DS
authors.lastname: Kim
authors.affiliation: Division of Cardiology, Jeju National University Hospital, Jeju, South Korea.
authors.forename: Seung Jae
authors.initials: SJ
authors.lastname: Joo
authors.affiliation: Division of Cardiology, Wonju Severance Christian Hospital, Wonju Medical College, Yonsei University, Wonju, South Korea.
authors.forename: Seung Hwan
authors.initials: SH
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, South Korea.
authors.forename: Kyung-Kuk
authors.initials: KK
authors.lastname: Hwang
authors.affiliation: Division of Medicine/Cardiology, Department of Internal Medicine, Cheil General Hospital, Dankook University College of Medicine, Seoul, South Korea.
authors.forename: Jeong Bae
authors.initials: JB
authors.lastname: Park
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000737:chemistry / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000737:chemistry / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology*; D013777:Tetrazoles / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D011743:Pyrimidines; D013777:Tetrazoles; C558933:fimasartan
keywords: angiotensin receptor blockers; blood pressure variability; hypertension